Type 2 Diabetes

Glycemic control monotherapy granted tentative approval by FDA

Published in Obesity and Diabetes Week, December 1st, 2003

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received tentative approval from the Office of Generic Drugs of the U.S. Food and Drug Administration (FDA) to manufacture and market Metformin Hydrochloride Extended-release Tablets, 500 mg.

Total market sales for all forms of Metformin were $1.6 billion with sales of $452.4 million for the Metformin Extended-release formulation (IMS - MAT: June 2003).

Metformin Hydrochloride Extended-release Tablets (Glucophage XR) as monotherapy is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2003-12-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry